Nonalcoholic fatty liver disease (NAFLD) is highly associated with insulin resistance (IR), type 2 diabetes mellitus and metabolic syndrome, being characterized as the hepatic component of metabolic syndrome. Despite its high prevalence, no pharmacological treatment has been established, as of yet. A growing body of evidence, however, shows that reducing IR can result in improvement of the biochemical and histological features of nonalcoholic steatohepatitis (NASH)-the aggressive form of NAFLD that can lead to cirrhosis and hepatocellular carcinoma. Unfortunately, the several trials that have assessed the effect of various antidiabetic agents to date have failed to establish an effective and safe treatment regimen for patients with NAFLD. Glucagon-like peptide-1 (commonly known as GLP-1) agonists are a novel class of antidiabetic drugs that improve insulin sensitivity and promote weight loss. They also appear to have a direct effect on the lipid metabolism of hepatocytes, reducing hepatic steatosis. Several trials have demonstrated that GLP-1 agonists can reduce aminotransferase levels and improve liver histology in patients with NAFLD, suggesting that these agents could serve as an alternative treatment option for these patients. This manuscript discusses the role and potential mechanisms of GLP-1 agonists in the treatment of NASH.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) encompa sses a wide spectrum of clinical and histopathologi cal conditions, ranging from simple steatosis [i.e., nonalcoholic fatty liver (NAFL)] to liver injury [i.e., nonalcoholic steatohepatitis (NASH), the aggressive form of NAFLD that can lead to cirrhosis and hepa tocellular carcinoma] [1, 2] . NAFLD is highly associated with metabolic syndrome and type 2 diabetes mellitus (T2DM) [3] . In fact, the prevalence of NAFLD in T2DM has been estimated to be around 60% [4] . The pathophysiology of NAFLD is not yet fully elu cidated; however, it is widely believed that insulin resistance (IR) may play a critical role in the patho genesis of the disease. Several studies have shown that patients with NAFL and NASH are characterized by IR and hyperinsulinemia, irrespective of glucose tolerance or body mass index [5, 6] . The multihit hy pothesis, initially described by Day and James [7] , claims that IR is the key factor in the pathogenesis of steatosis. IR causes dysregulation of peripheral lipolysis and increases de novo lipogenesis, leading to elevated levels of circulating fatty acids and lipid accumulation within hepatocytesthe "first hit" that predisposes to liver injury, inflammation and fibrosis [8] . Disrupted insu lin signaling is also involved in inflammatory cascade activation, lipid peroxidation and liver injury"the se cond hit" leading to NASH [9] . Currently, NAFLD is reported to be the most com mon chronic liver disease worldwide [10] . However, despite huge efforts, there is still no established ph armacotherapy. Lifestyle modifications remain the sole therapeutic approach [11] . Given that IR is considered as the main pathogenetic factor for the development of NAFLD, drugs targeting IR have been investigated the most as potential treatment options for NAFLD, but the studies have yielded conflicting results.
Metformin, the most widely used insulinsensitizing agent, improves insulin sensitivity by mechanisms that are not yet fully understood [12] . A metaanalysis assessing the effect of metformin in NAFLD revealed that, while it can improve the biochemical and me tabolic features of NAFLD, it does not improve the patients' histological response [13] . Metformin is not currently recommended for the treatment of NAFLD by either the American Association for the Study of Liver Diseases or the European Association for the Study of Liver (commonly referred to by their acronyms, AASLD and EASL, respectively) [14, 15] . Thiazolidinediones, another class of insulinsen sitizers, act by redistributing fat from ectopic tissues to the adipose tissue, and by increasing levels of adi ponectinan adipokine that has insulin-sensitizing pro perties [16, 17] . Several studies have evaluated the effi cacy of thiazolidinediones in patients with NAFLD. The "Pioglitazone vs vitamin E vs placebo for the treatment of nondiabetic patients with nonalcoholic steatohepati tis" trial (published as the PIVENS trial) was the largest one performed, involving 247 nondiabetic patients with biopsyproven NASH [18] . The patients were randomized to receive either pioglitazone (30 mg/d) or vitamin E (800 IU/d) or placebo. The pioglitazone treatment was associated with a significant reduction in steatosis and lobular inflammation compared to placebo; however, it did not improve fibrosis. A randomized, placebo controlled trial performed in patients with NASH and prediabetes or T2DM showed that pioglitazone achieved the primary endpoint of an ≥ 2point decrease in NAFLD activity score without worsening fibrosis, and was as sociated with improvement in steatosis, inflammation and ballooning necrosis [19] . The AASLD and EASL have suggested the use of pioglitazone in patients with biopsy-proven NASH [14, 15] , although concerns about the side effects and longterm safety of this drug have limited its widespread use. Pioglitazone has been asso ciated with weight gain that is persistent (even after discontinuation of the treatment), fluid retention, dete rioration of heart failure, bone fractures, and increased risk of bladder cancer [2023] .
ROLE OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS IN NAFLD
Glucagonlike peptide1 (GLP1) agonists represent a novel class of antidiabetic drugs. They mimic the action of endogenous GLP1, a gastrointestinal hormone of the incretin class of proteins that is secreted from Langerhans cells in response to nutrient ingestion [24] . This hormone has several metabolic effects, including the stimulation of glucosedependent insulin secretion, inhibition of glucagon release, induction of pancreatic βcell proliferation, and delay of gastric emptying [25] . While native GLP1 is rapidly degraded by the enzyme dipeptidy1 peptidase4 (otherwise known as DPP4), GLP1 agonists have increased resistance to DPP4, thus prolonging the halflife time [26] . These agents have been shown to have beneficial effects on IR and weight control [25] . Several studies have demonstrated the the pioglitazone group and did not retain a statis tically significant difference for the sitagliptin group. Administration of liraglutide was identified as an inde pendent factor for body weight reduction in multivariate analysis.
In a recent openlabel trial by Feng et al [32] , 87 patients with NAFLD were randomized to receive lira glutide, metformin or gliclazide for 24 wk. All three groups showed reduced intrahepatic fat, but the lira glutide group had the greatest reduction. In addition, the researchers found a statistically significant decrease in serum AST and alanine aminotransferase levels only in the liraglutide and metformin group, reporting slightly better results for the liraglutide group. However, a study by Khoo et al [33] demonstrated that liraglutide was as effective as structured lifestyle modification for reduction of liver fat fraction and serum aminotransferase levels.
Exenatide
Two trials examined the use of exenatide in patients with NAFLD and T2DM [34, 35] . In the first, Shao and collea gues [34] studied 60 patients with NAFLD and T2DM [34] . The patients were randomized to receive exenatide plus insulin glargine U100 (exenatide group) or insulin glargine U100 plus insulin aspart (intensive insulin group) for 12 wk. The levels of alanine aminotransferase, AST, and gammaglutamyl transferase were significantly lower in the exenatide group than in the intensive insulin group. The exenatide plus insulin glargine treatment was also found to be superior to the intensive insulin therapy concerning the reversal rate of fatty liver (93.3% vs 66.7%, respectively). The second study, conducted by Fan et al [35] , compared the efficacy of exenatide versus metformin in patients with NAFLD and T2DM. The results revealed that exenatide was more effective than metformin in reducing body weight and improving liver enzymes. Nevertheless, the efficacy of exenatide has not been evaluated in randomized trials with histological outcomes in patients with NASH, as of yet. Lastly, a recent metaanalysis of six studies assessing the efficacy of GLP1 agonists (liraglutide and exenatide) in NAFLD, revealed that these agents improve liver histology and reduce serum aminotransferase levels, indicating that they might be effective in patients with biopsyproven NASH [36] .
Semaglutide
Semaglutide is a novel longacting GLP1 analogue, and has been recently approved for T2DM [37] . It has 94% sequence homology to human GLP1 and a half life of 165 h, supporting a once weekly scheme of administration [38] . Semaglutide has shown beneficial effects on glucose control and weight loss compared to placebo and other antidiabetic drugs in patients with T2DM in the "SUSTAIN" trial program [37, 38] . It is currently under investigation for its potential as a treatment option for patients with NASH. A 72wk, randomized, doubleblind trial of 372 patients comparing the effi presence of GLP1 receptor in hepatocytes, implying that GLP1 agonists may also exert a direct effect on the liver. Gupta et al [27] found that the GLP1 receptor plays a key role in the decrease of hepatic steatosis in vitro, by modulating elements of the insulin signaling pathway. GLP1 agonists have demonstrated protec tion of hepatocytes from fatty acidrelated death by prohibition of a dysfunctional endoplasmic reticulum stress response. They also appear to reduce fatty acid accumulation by activation of both macroautophagy and chaperonemediated autophagy [28] . Evidence suggests that GLP1 secretion is impaired in pati ents with NAFLD and NASH, highlighting the role of GLP1 agonists as potential candidates for NAFLD treatment [29] .
Liraglutide
Multiple trials have evaluated the efficacy of GLP 1based therapies in NAFLD. Among the GLP1 ago nists, liraglutide is the most widely studied drug. In the "Liraglutide Efficacy and Action in NASH" study (published as the LEAN study), a doubleblind rando mized control trial, Armstrong et al [30] assessed the effect of 48 wk of treatment with liraglutide in patients with biopsyproven NASH. Fiftytwo patients with (n = 17) or without (n = 35) T2DM were randomly allocated to receive either liraglutide (1.8 mg/d) or placebo. The primary endpoint of the study was the resolution of definite steatohepatitis without worsening fibrosis. Secondary histological endpoints included change in the overall NAFLD activity score (steatosis, ballooning, lobular inflammation) and its individual components. Overall, 9/23 patients in the liraglutide group showed resolution of NASH with no worsening fibrosis com pared to 2/22 patients in the placebo group (P = 0.019), successfully meeting the primary endpoint. Regarding the secondary outcomes, fewer patients in the liraglutide group showed progression in fibrosis compared to the placebo group (2/23 vs 8/22, P = 0.04). However, results concerning lobular inflammation and overall NAFLD activity score were not statistically significant when compared between the two groups. The authors used histological primary endpoints, being able to evaluate the direct effect of liraglutide on the liver. The study was performed on patients with biopsy proven NASH, avoiding the inclusion of those without definite NASH. Their findings suggested that liraglutide led to the histological resolution of NASH, with the small sample size being, however, a major limitation. Ohki et al [31] performed a retrospective cohort study evaluating the efficacy of liraglutide compared to sitagliptin and pioglitazone in patients with NAFLD.
They reported a significant reduction in serum amino transferase levels for all groups, while the aspartate aminotransferase (AST)toplatelet counts ratio index was significantly reduced only for the liraglutide and pioglitazone groups. Body weight significantly decr eased in the liraglutide group, while it increased in cacy and safety of three dose levels of subcutaneous semaglutide once daily vs placebo in NASH patients is ongoing (NCT02970942). This trial is expected to be completed during 2019 and will provide additional information on the effectiveness of GLP1 agonists in patients with NAFLD.
CONCLUSION
GLP1 agonists are not currently recommended by the AASLD and EASL for the treatment of NAFLD. In their latest guidelines, it was pointed out that it is still premature to consider these agents as a specific treatment for patients with NASH without diabetes, due to inadequate evidence [14, 15] . Future research is, therefore, needed to confirm their efficacy in these patients.
In conclusion, current evidence suggests that GLP1 agonists may be an attractive therapeutic option for patients with NAFLD. However, larger studies of longer duration with histological endpoints are still required to establish their exact role in the management of NAFLD.
Perspective for future study GLP1 agonists have been shown to be effective in improving liver histology and reducing aminotransferase levels in patients with NASH. So, the question arises as to whether these agents could serve as a treatment option for such patients. While data are promising, they are still limited. Largescale randomized, placebo controlled trials with complete histological outcomes are warranted to elucidate the efficacy of GLP1 ago nists in treating NASH. Another major limitation of the currently available studies is the lack of longterm outcomes. Studies of longer duration are required to properly evaluate the histological improvement in NASH. What is more, it would be interesting if future trials would include both diabetic and nondiabetic pati ents, in order to clarify the effect of GLP1 agonists in NASH, regardless of changes in glycemic control. It will also be significant to assess whether GLP1 agonists affect NAFLD in a dosedependent manner, in order to search for preferred doses.
